Lilly gets approval for earlier use of Jaypirca in CLL
Eli Lilly's fast-growing Jaypirca has won a new FDA approval as an earlier treatment for relapsed/refractory chronic lymphocytic leukaemia.
Newsletters and Deep Dive digital magazine
Eli Lilly's fast-growing Jaypirca has won a new FDA approval as an earlier treatment for relapsed/refractory chronic lymphocytic leukaemia.
Tracy Beth Høeg, who has very little regulatory experience, is making the switch from CBER to replace FDA veteran Richard Pazdur.
In this sponsored podcast, Cheryl Lubbert and Carolyn Whiting of Reverba discuss a new approach to pharma marketing, omnichannel, and medical affairs.
A US appeals court has reversed a 2023 decision that ordered Daiichi Sankyo to pay royalties on sales of cancer drug Enhertu to Seagen (now Pfizer).
Seeking a lead over rival Mineralys, AstraZeneca is using a priority review voucher for its US filing for uncontrolled hypertension drug baxdrostat.
Editor's Picks
Newsletters and Deep Dive
digital magazine